327 filings
ARS
2023 FY
AUPH
Aurinia Pharmaceuticals Inc
3 May 24
Annual report to shareholders
4:16pm
DEFA14A
AUPH
Aurinia Pharmaceuticals Inc
3 May 24
Additional proxy soliciting materials
4:11pm
DEF 14A
AUPH
Aurinia Pharmaceuticals Inc
Definitive proxy
3 May 24
4:08pm
10-Q
2024 Q1
AUPH
Aurinia Pharmaceuticals Inc
Quarterly report
2 May 24
6:07am
8-K
AUPH
Aurinia Pharmaceuticals Inc
2 May 24
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
6:03am
8-K
sn41ei5na8
29 Feb 24
Departure of Directors or Certain Officers
4:10pm
8-K
py1mo
15 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
6:06am
8-K
7zie95
5 Jan 24
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2023 Net Revenue Results
6:02am
8-K
ln60d372nb
2 Nov 23
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
6:01am
8-K
5tut55r8ci5 zda
21 Sep 23
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director
4:06pm
8-K
kb10xpht7nshdx
21 Aug 23
Dr. Daniel G. Billen appointed Chair of the Board of Directors
4:11pm
8-K
ram10 4fj4dv
3 Aug 23
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
6:03am
PX14A6G
war85m73
6 Jul 23
Letter to shareholders
8:33am
8-K
5d3xvjic6qvf
3 Jul 23
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
6:06am
PX14A6G
shicusphz3h82mgn3
1 Jun 23
Letter to shareholders
2:01pm
S-8
vrd1ujrxw8 k1qrxi
26 May 23
Registration of securities for employees
4:39pm